详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China.

61| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [2]Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. [3]Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China. [4]Department of Breast Surgery, Henan Cancer Hospital, Zhengzhou, China. [5]Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. [6]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. [7]Department of Breast Cancer, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China. [8]Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. [9]Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. [10]Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China. [11]Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [12]Department of Breast Surgery, Sichuan Province Tumor Hospital, Chengdu, Sichuan, China. [13]Department of Medical Oncology, Yunnan Cancer Hospital, Kunming Medical University, Kunming, China. [14]Department of Breast Surgery, Cancer Hospital, Guangxi Medical University, Nanning, Guangxi, China. [15]Departments of Medical Oncology and Thoracic Surgery, The First Hospital of China Medical University, Shenyang, China. [16]Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Key Laboratory of Liaoning Breast Cancer Research, Shenyang, China. [17]The 4th Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. [18]Department of the Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing, China. [19]Department of Medicine Oncology, Fuzhou General Hospital of Nanjing Military Command, Fuzhou, China. [20]Department of Breast Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. [21]Department of Oncology, The General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China. [22]Department of Breast Cancer and Lymphoma, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.

出处：

DOI：

ISSN：

摘要：

To better understand the status of medical treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer and the differences between the Chinese and the international clinical practice.This was a retrospective, nationwide, multicenter, epidemiological study of advanced breast cancer patients from China. Between January 01, 2012, and December 31, 2014, a total of 3649 patients, covering 7 geographic regions and 21 institutions, participated in this series of studies. HER2-positive breast cancer was selected among the group and adopted into this study. In comparison, we summarized the demographics and clinical characteristics of HER2-positive breast cancer from the Surveillance, Epidemiology, and End Results (SEER) database.A total of 918 patients diagnosed as HER2-positive breast cancer patients were included. The median age at diagnosis was 46 years (ranging, 23 to 78) with a single-peak incidence. The proportions of stages II-IV at diagnosis and distance metastasis in viscera were more than half of the participants. In comparison, the prevalence of estrogen or progesterone receptor-positive expression and luminalB subtype was relatively lower than that of the United States. The receipt of chemotherapy was fairly higher, while the usage of targeted therapy was seriously insufficient. Tumor size was in significantly positive associations with the duration of targeted therapy (Kendall's correlation coefficient = 0.3, P < 0.0001), while no prohibitive variables among clinical characteristics were detected.Our study suggested that HER2-positive breast cancer patients were characterized as a younger trend, a lower prevalence of hormonal receptor (HR)-positive expression, and less accessible to anti-HER2 targeted therapy with insufficient duration over the past few years in China. Concerted efforts should be exerted for promising survival benefits in the future. The trial registration number is https://clinicaltrials.gov/ct2/show/NCT03047889.Copyright © 2021 Yi-Qun Han et al.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 4 区肿瘤学

最新[2023]版：

无

JCR分区：

出版当年[2020]版：

Q2 ONCOLOGY

最新[2023]版：

无

影响因子： 0 最新[2023版] 0 最新五年平均 4.375 出版当年[2020版] 4.499 出版当年五年平均 2.206 出版前一年[2019版] 4.501 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：